US equities
|
INTC
$112.50
▲+0.00%
MU
$1,045.56
▲+0.00%
SNDK
$1,660.46
▲+0.00%
NVDA
$239.24
▲+0.00%
SPCX
$171.92
▲+0.00%
MRVL
$287.01
▲+0.00%
AMD
$649.42
▲+0.00%
MSTR
$164.55
▲+0.00%
INTC
$112.50
▲+0.00%
MU
$1,045.56
▲+0.00%
SNDK
$1,660.46
▲+0.00%
NVDA
$239.24
▲+0.00%
SPCX
$171.92
▲+0.00%
MRVL
$287.01
▲+0.00%
AMD
$649.42
▲+0.00%
MSTR
$164.55
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Marinus Pharmaceuticals
< Previous
1
2
3
4
Next >
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
November 12, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
October 24, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
October 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
October 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
October 09, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 08, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
September 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
September 12, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
August 19, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
July 30, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
July 18, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
June 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
May 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
May 02, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
May 01, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
April 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
March 27, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 21, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 16, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
November 20, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
< Previous
1
2
3
4
Next >
